topotecan has been researched along with pentetic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Blank, E; Ceriani, R; Furmanski, P; Hochster, H; Kramer, E; Liebes, L; Ng, B; Wasserheit, C | 1 |
1 review(s) available for topotecan and pentetic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for topotecan and pentetic acid
| Article | Year |
|---|---|
Radiosensitization of tumor-targeted radioimmunotherapy with prolonged topotecan infusion in human breast cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Bone Marrow; Breast Neoplasms; Cell Division; Combined Modality Therapy; Drug Synergism; Enzyme Inhibitors; Female; Humans; Immunoglobulin G; Immunotoxins; Mice; Mice, Nude; Pentetic Acid; Radiation Tolerance; Radioimmunotherapy; Topotecan; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2001 |